Biotech Conference Coverage Day 4 Session 4 - Alterity Therapeutics Limited

ATHE (quick overview): Alterity is advancing ATH434 for multiple system atrophy, with Phase 2 showing a reported 48% slowing in functional decline at 50 mg and a 2.7–3.7-point drug–placebo difference versus the roughly 1.5-point clinically meaningful threshold. An FDA-aligned Phase 3 path supports the opportunity, but the small prior study, non-linear dose response, multi-year timeline and need to fund the pivotal trial remain material risks and keep it from being a top M&A setup.

Read full article (2 min)